Compare Novartis AG (NVS) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Rockwell Automation — how do they compare? Novartis AG trades at $139.47 (market cap $262.64B), while Rockwell Automation trades at $426.07 (market cap $47.65B). The key difference: Novartis AG is far larger — about 5.5× Rockwell Automation's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | ROK | |
|---|---|---|
Market Cap | $262.64B | $47.65B |
Sector | Health | Industrials |
52-Week High | $168.62 | $495.08 |
52-Week Low | $121.80 | $333.75 |
Enterprise Value | $303.97B | $50.79B |
Dividend Yield | 3.44% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and near-term support at $427. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34B, with a net income margin of 13.38%, though profitability has moderated from 2023 peaks. Recent news highlights expansion in AI-driven quality systems and remote support capabilities.
The stock offers a 19.8% upside to the consensus price target of $514, supported by analyst optimism on margin expansion and reshoring trends. However, high valuation multiples (P/E 40.18) and mixed technical indicators suggest near-term volatility. Key risks include execution on growth initiatives and macroeconomic pressures on industrial spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
